Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer's disease in community cohorts.

ABSTRACT:

Background

Plasma p-tau217 is a promising biomarker for detecting incipient AD pathology, but direct comparison of different p-tau217 assays in community-based cohorts are limited.

Methods

We evaluated two cohorts from southwestern Pennsylvania, USA; the MYHAT-NI sub-study, which included two-year longitudinal follow-up neuroimaging assessments of Aβ, tau, and cortical thickness; and the Human Connectome Project/CoBRA, targeting a 50:50 split of self-identified Black and non-Hispanic White individuals. Plasma p-tau217 was measured using four different assays: Lumipulse, Johnson&Johnson, ALZpath, and NULISA. Aβ and tau pathologies were assessed with [¹¹C]PiB PET and [¹⁸F]Flortaucipir PET, respectively. Clinical Dementia Rating (CDR) and Montreal Cognitiv

SUBMITTER: Deek RA 

PROVIDER: S-EPMC12632664 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature